Insider Buying: STAAR Surgical (NASDAQ:STAA) Major Shareholder Buys $1,952,611.20 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 108,720 shares of the business’s stock in a transaction that occurred on Thursday, March 20th. The shares were acquired at an average cost of $17.96 per share, with a total value of $1,952,611.20. Following the completion of the purchase, the insider now owns 12,182,995 shares of the company’s stock, valued at approximately $218,806,590.20. The trade was a 0.90 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Tuesday, March 18th, Broadwood Partners, L.P. acquired 93,124 shares of STAAR Surgical stock. The shares were bought at an average price of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. bought 249,503 shares of STAAR Surgical stock. The stock was bought at an average price of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. purchased 36,532 shares of STAAR Surgical stock. The stock was bought at an average cost of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock. The shares were purchased at an average cost of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock. The stock was purchased at an average cost of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. purchased 21,155 shares of STAAR Surgical stock. The stock was purchased at an average price of $21.46 per share, with a total value of $453,986.30.

STAAR Surgical Stock Performance

Shares of STAA opened at $17.72 on Friday. The firm has a market cap of $874.04 million, a PE ratio of -43.22 and a beta of 0.66. The firm’s 50 day moving average price is $19.87 and its 200 day moving average price is $25.66. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $52.68.

Wall Street Analysts Forecast Growth

STAA has been the topic of several recent analyst reports. Mizuho downgraded shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and cut their target price for the company from $45.00 to $17.00 in a research note on Wednesday, February 12th. Stephens reissued an “equal weight” rating and issued a $17.00 price objective on shares of STAAR Surgical in a research note on Tuesday, March 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research note on Thursday, February 27th. William Blair lowered shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 12th. Finally, StockNews.com downgraded shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and a consensus price target of $25.29.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in STAAR Surgical by 13.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 110,506 shares of the medical instruments supplier’s stock worth $2,684,000 after buying an additional 13,075 shares during the last quarter. Voloridge Investment Management LLC boosted its stake in shares of STAAR Surgical by 9.4% during the 4th quarter. Voloridge Investment Management LLC now owns 296,256 shares of the medical instruments supplier’s stock worth $7,196,000 after acquiring an additional 25,350 shares in the last quarter. Squarepoint Ops LLC increased its holdings in shares of STAAR Surgical by 81.3% during the 4th quarter. Squarepoint Ops LLC now owns 117,074 shares of the medical instruments supplier’s stock valued at $2,844,000 after acquiring an additional 52,488 shares during the last quarter. Sherbrooke Park Advisers LLC bought a new position in shares of STAAR Surgical in the 4th quarter valued at approximately $502,000. Finally, Raiffeisen Bank International AG acquired a new stake in STAAR Surgical in the 4th quarter worth approximately $1,926,000. Institutional investors own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.